Backed by a pi­o­neer in BiTE tech, Har­poon marks a course for an IPO and an ear­ly dis­play of po­ten­tial

Can a next-gen BiTE de­vised by a pi­o­neer in the field at­tract in­vestors in­to an on­col­o­gy IPO based al­most en­tire­ly on mouse da­ta? Har­poon Ther­a­peu­tics plans to find that out in ear­ly 2019.

The biotech has filed an $86 mil­lion IPO, just a few months af­ter rais­ing $70 mil­lion in its lat­est ven­ture round. The com­pa­ny al­so spelled out some of the de­tails in its al­liance with Ab­b­Vie, which came with a $17 mil­lion up­front and hun­dreds of mil­lions more in mile­stones on the ta­ble.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.